THE UNIVERSITY OF TEXAS 
M.D. ANDERSON CANCER CENTER 
Division of Medicine 
Protocol Title: Use of Retroviral Markers to Identify 
Efficacy of Purging and Origin of Relapse 
Following Autologous Bone Marrow 
Transplantation in Chronic Lymphocytic 
Leukemia ( CLL) Patients 
1.0 OBJECTIVES 
2 . 0 BACKGROUND 
3 . 0 BACKGROUND DRUG INFORMATION 
4.0 PATIENT ELIGIBILITY 
5.0 TREATMENT PLAN 
6 . 0 PRE-TREATMENT EVALUATION 
7.0 EVALUATION DURING STUDY 
8.0 CRITERIA FOR RESPONSE AND TOXICITY 
9 . 0 CRITERIA FOR REMOVAL FROM STUDY 
10.0 STATISTICAL CONSIDERATIONS 
11.0 
REFERENCES 
APPENDIX Al: 
APPENDIX A2 : 
APPENDIX B: 
APPENDIX C: 
APPENDIX D: 
APPENDIX E: 
APPENDIX F: 
APPENDIX G: 
APPENDIX H: 
APPENDIX I: 
CONSENT FORM 
Zubrod Scale 
Cardiac Status Scale 
Clinical Protocols:. Human Gene Transfer 
Proposal 
Investigational Drug Data Sheet: 
Cyclophosphamide 
Investigational Drug Data Sheet: Etoposide 
Investigational Drug Data Sheet: Interferon 
Gene-Transfer Virus Article 
Preparation of Marking Vector 
Toxicity Criteria 
Evaluation Before and During Therapy 
Study Chairman : 
Albert Deisseroth, M.D., Ph.D. 
Study Co-Chairman : 
Hagop Kantarjian, M.D. 
t 
Richard Champlin, M.D. 
Recombinant DNA Research, Volume 16 
[385] 
/ 
